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Abstract Chronic subdural haematoma (CSDH) is a com-
mon neurological condition that usually affects the elderly.
The optimal treatment strategy remains uncertain, principal-
ly because there is a lack of a good evidence base. In this
paper, we review the literature concerning the peri-operative
and operative care of patients. In particular, we highlight the
non-surgical aspects of care that might impact on patient
outcomes and CSDH recurrence. We propose that an inte-
grated approach to care in patients with CSDH, similar to
care of fragility fractures in the elderly, may be an important
strategy to improve patient care and outcomes.
Keywords Chronic subdural haematoma . CSDH . Elderly .
Peri-operative care . Outcomes
Introduction
The incidence of chronic subdural haematoma (CSDH) in-
creases with age, and after 70 years of age is 8·2/100,000/year
[1]. As the population ages, the prevalence is anticipated to
increase [1, 2]. CSDH is an important cause of morbidity and
mortality and it has been described as a ‘sentinel health event’
indicating underlying systemic pathology. CSDH has a 1-year
mortality similar to that of hip fractures [2].
It is surprising then that little class I evidence exists to
describe the optimal surgical and peri-operative management
of CSDH. This is important, because improving outcomes in
this elderly and often frail population requires us to make
informed decisions at all stages of their management, not just
in the operating theatre. We need to understand the impact of
both surgical and non-surgical treatment decisions on patient
outcomes and CSDH recurrence.
The peer-reviewed literature actually offers often conflict-
ing advice regarding CSDH management, leading to consid-
erable variation in practice. For example, the most common
surgical strategy for evacuation of a CSDH is burr hole crani-
otomy, but the optimal number of burr holes (one vs. two) is
uncertain [3, 4]. Post-operatively, there is also contradictory
advice about the relative risk of bed rest and early mobilisation
on CSDH recurrence or post-operative morbidity [5–7]. Other
uncertainties include the benefit of corticosteroids as either a
primary treatment or an adjunct to surgery and the need to
administer agents to mitigate the biological effects of anti-
platelet medication pre-operatively (e.g., platelet transfusion)
[8, 9]. We will review these in more detail.
Clinical uncertainties create potential risk for elderly pa-
tients. A sound evidence base is therefore urgently needed.
Crucially, this should focus not only on surgical practice, but
should also take into account all stages of the patient pathway
from diagnosis to rehabilitation. We review the evidence base
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for the peri-operative and operative care of patients with
CSDH. In particular, we discuss the non-surgical interventions
that might facilitate patient recovery and rehabilitation.
Pathophysiology
CSDH is a collection of liquefied blood between the dura and
arachnoid layer of the brain thought to result from injury to
bridging veins crossing the subdural space. Head injury is a
common risk factor and in a study of 1000 patients, 61.7 %
recalled a recent one [10]. Other risk factors include coagu-
lopathy, use of antiplatelet or anticoagulant medication, over-
drainage from a cerebrospinal diversion device, haematologi-
cal malignancies and vascular malformations [11••].
CSDHs often present several weeks or months after the
index bleed, because as the initial acute haematoma liquefies
it enlarges. This increasing volume causes mass effect that
manifests clinically. Two principal theories have been pro-
posed for the mechanism of clot enlargement. Firstly, that
the liquefying clot has increased protein content exerting an
osmotic effect through increased oncotic pressure. However,
the osmolality of the liquefied clot is actually the same as
cerebrospinal fluid and blood [12]. A second theory states that
recurrent bleeding occurs from abnormal and dilated blood
vessels in the capsule that forms around the haematoma.
Evidence from radiolabelling studies and observation of co-
agulation abnormalities within the CSDH itself support this
theory [13]. High concentrations of vascular endothelial
growth factor (VEGF) have also been demonstrated within
the subdural fluid supporting the theory that ongoing angio-
genesis and hyper-permeability of capillaries contributes to
haematoma expansion [13].
Clinical Presentation
Patients with chronic subdural haematomas can present in a
variety of ways, and symptom onset and progression may
range from days to weeks. Elderly patients frequently present
with multiple symptoms that may mimic a stroke or rapidly
progressive dementia. In a study of 1000 patients with CSDH,
their presenting symptoms included behavioural disturbance
(28.5 %), headaches (25.1 %), and limb weakness (24.8 %);
behavioural disturbance was the predominant clinical feature
in elderly patients [10]. Many patients have a mild reduction
in their level of consciousness (Glasgow Coma Scale [GCS]
score of 13–15), but elderly patients with CSDH do not typi-
cally present in coma [14••, 15•]. Bilateral subdural
haematomas may be present in up to 25 % of patients, but
without causing focal neurological deficits [13, 16]. Midline
shift may be minimal with bilateral CSDH, but the
haematomas can still exert significant mass effect. This may
increase the risk of rapid deterioration, so consideration may
be given to expedited surgical drainage in these patients.
Management
Surgical Management
Surgical haematoma evacuation is indicated in patients who
deteriorate or do not improve. Surgery can bring a rapid clin-
ical improvement with a favourable outcome in over 80 % of
patients [1]. However, the most effective surgical technique is
uncertain. The three most common techniques are twist-drill
craniotomy (TDC), burr hole craniotomy (BHC) and craniot-
omy. TDC involves making a skull opening of <5 mm and
can be performed at the bedside. BHC and craniotomy are
performed in the operating theatre; the former involves mak-
ing one or two holes <30 mm in diameter in the skull, where-
as craniotomy is generally defined as creating a >30-mm
diameter bony defect which is replaced at the end of the
procedure. Several studies including a recent large prospec-
tive multi-centre audit of CSDH management in the UK
found BHC to be the most frequently used method of surgical
drainage [17••, 18•].
Comparison of Operational Techniques
Most studies comparing surgical techniques have been small,
single-centred and retrospective. Weigel and colleagues per-
formedmeta-analyses of the available data. They reported that
whilst all three techniques have approximately the same mor-
tality (2–4 %), craniotomy has significantly higher morbidity
and TDC has a higher rate of recurrence, suggesting BHC is
the preferred technique [19]. A Monte Carlo decision analysis
by Lega et al. also favoured BHC over TDC or craniotomy,
given its low recurrence and complication rate [20]. Ducruet
et al. concluded that TDC should be the first-line treatment for
patients who are high-risk surgical candidates with non-
septated CSDH, whilst craniotomy is reserved for patients
with membranous CSDH or symptomatic recurrence.
Ducruet did not specifically compare TDC to BHC, but a
more recent meta-analysis by Almenawer et al. found no sig-
nificant differences between TDC and BHC in mortality, mor-
bidity or recurrence rates [18•]. However, there was a trend
towards lower complication rates in patients treated with TDC
[18•].
Number of Burr Holes
Current evidence then suggests that TDC or BHC should be
first-line treatment in the majority of patients with CSDH. The
number of burr holes used depends on individual surgeon
preference. A meta-analysis of 631 patients failed to
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demonstrate a significant difference in recurrence rates related
to the number of burr holes used, so single BHC appears as
good as double BHC [21]. Similarly, a recent large UK audit
did not demonstrate number of burr holes as an independent
risk factor for CSDH recurrence [17••]. Perhaps the default
surgical method should be a single burr hole, reducing oper-
ating time and potentially morbidity. Crucially, this may also
permit the procedure to be performed under local anaesthetic,
an attractive option in patients with cardio-respiratory morbid-
ity. This hypothesis needs to be formally tested.
Irrigation
During surgical evacuation of a CSDH, opening of the dura to
release the haematoma often reveals that the collection was
under tension. This release of pressure may be sufficient to
improve the patient’s clinical state and the role of additional
intra-operative irrigation remains unclear. One study of 247
patients demonstrated a significant reduction in recurrence
rates when more than 1500 ml of irrigation fluid is used
[22]. However, a recent meta-analysis demonstrated no clear
evidence of improvement in outcomes [18•].
Use of Post-operative Drains
The most evidence-based adjunct to surgical haematoma
evacuation is placement of a post-operative drain. A
randomised controlled trial (RCT) demonstrated that subdural
drains left in situ after BHC reduced CSDH recurrence requir-
ing re-drainage (9·3 vs. 24·0 % recurrence with/without drain)
[14••]. The benefit of drains was confirmed by three recent
meta-analyses, and the placement of closed-system drainage is
now standard practice [18•, 23, 24]. Some surgeons prefer
placement of a less-invasive subperiosteal drain and it has
been recommended that subperiosteal drains are placed in
patients over 80 years of age or in those with predicable high
risk for complications [25]. A direct comparison between sub-
dural and subperiosteal drain placement has yet to be made.
Non-surgical Management
In patients with mild symptoms such as minor headache, or in
patients deemed unfit for surgery, there may be a role for
‘watchful waiting’. Serial cranial imaging may provide infor-
mation to support decision-making, but the success or other-
wise of this strategy should be guided by clinical assessment.
As yet, there are no evidence-based guidelines on the frequen-
cy of serial imaging.
Corticosteroids
Some surgeons recommend a course of corticosteroids. Since
spontaneous resolution of CSDH can occur, it is difficult to
know whether corticosteroids speed up this process.
Spontaneous resolution is thought to occur when the vascular
membrane around the haematoma matures, bringing an end to
the recurrent small bleeding that increases or maintains the
size of the haematoma. Corticosteroids may facilitate this pro-
cess by down-regulating the inflammatory reaction that is
thought to maintain the vascularised haematoma membrane
[26]. The hypothesis that corticosteroids negate the need for
surgery in some symptomatic patients and reduce the rate of
recurrence in other surgically treated patients is principally
derived from non-randomised studies [8, 25]. However, two
prospective RCTs currently recruiting aim to definitively clar-
ify the role of corticosteroids. Dex-CSDH is a multi-centre
randomised, double blind, placebo-controlled trial of a 2-
week course of tapering dexamethasone for adults with symp-
tomatic CSDH (ISRCTN 80782810). This will assess the clin-
ical status of the patients 6 months post-randomisation
through objective disability scales, whilst also establishing
progression to surgical intervention and recurrence rates in
each group. The Dresh study is a double blind, placebo-
controlled RCT [27]. It differs from Dex-CSDH in that the
medication is prescribed post-operatively for 6 days. The end
point is reoperation rates at 12 weeks.
Angiotensin Converting Enzyme Inhibitors
It has been hypothesised that the concurrent treatment of hy-
pertension with angiotensin converting enzyme (ACE) inhib-
itors in patients with CSDHmight lower the risk of recurrence
after surgery. ACEI might also lower the risk of developing
CSDH through their antiangiogenic mechanism [28]. A trial
to assess whether treatment with an ACE inhibitor for
3 months after surgical evacuation of CSDH will decrease
the risk of recurrence is ongoing (NCT00915928).
Peri-operative Care of Elderly Patients with CSDH
The 2001National Service Framework (NSF) for older people
recognised that care of the elderly patient in hospital is com-
plex [29]. It recommends that older people be given early
supervision and advice from a specialist team on hospital ad-
mission. The increased risk of peri-operative complications
with advancing age in part reflects a higher incidence of
coexisting disease and polypharmacy.
Anticoagulation and Antiplatelet Therapy
In a recent national UK audit of CSDH management, 43 % of
patients were admitted on an anticoagulant or antiplatelet
medication, similar to previously published figures [30].
Anticoagulant and antiplatelet use are both implicated in
CSDH development and recurrence [31]. Warfarin may in-
crease the risk of CSDH development up to 42.5 times [30].
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The increased risk from aspirin appears less [30]. The relative
risk of developing a CSDH whilst taking newer antiplatelet
medications has not yet been studied. The correct peri-
operative management of anticoagulant and antiplatelet med-
ication is therefore extremely important.
Anticoagulant Medication
The required speed of reversal of anticoagulant and antiplate-
let effects to minimise intra- and post-operative bleeding com-
plications will partly depend on the clinical urgency of sur-
gery. Vitamin K usually provides a more gradual normalisa-
tion of the international normalised ratio (INR), but may be
used in conjunction with fresh frozen plasma (FFP), pro-
thrombin complex concentrate (PCC) or recombinant factor
VIIa (rfVIIa) to speed up reversal and avoid INR rebound
[32]. FFP can promote fluid overload in elderly patients and
may precipitate cardiac or renal impairment, so PCC may be
preferred as an adjuvant to vitamin K [32, 33].
Resumption of anticoagulation therapy following surgery
should be done cautiously, but the risk of recurrent haemor-
rhage must be weighed against increased risk of thromboem-
bolic complications with prolonged discontinuation of
anticoagulation. There is little good quality evidence in this
area. There is a suggestion that oral anticoagulation may be
recommended 3 days after surgery in patients with a high
thromboembolic risk (e.g., patients with mechanical heart
valves) [34]. The CHA2DS2-VASc thromboembolism risk
score and the HAS-BLED bleeding risk score may help in-
form the timing in patients with atrial fibrillation [35].
Antiplatelet Medication
The effects of aspirin last until there is a 20 % new circulating
platelet mass, which usually occurs 5 days after cessation of
medication [36]. Clopidogrel produces abnormal bleeding for
approximately the same duration after discontinuation [37].
Anecdotally, in patients with minor symptoms, surgery is
therefore usually delayed for 7–10 days. However, the only
study to directly examine the effects of delaying surgery on
the recurrence rates of CSDH found surgery had to be delayed
for only 3 days after stopping antiplatelet medications to re-
duce risk of recurrence [38]. Reducing the length of time
patients wait for surgery may reduce other peri-operative mor-
bidity. For emergency surgery, the American Society of
Haematology recommends that patients previously taking as-
pirin or clopidogrel should be given a pre-operative platelet
transfusion [39]. However, these recommendations do not
pertain specifically to CSDH and there is no direct evidence
that platelet transfusion positively influences outcomes for
patients with CSDH.
Newer antiplatelet agents include a direct thrombin inhibitor
(Dabigatran), an indirect Factor Xa inhibitor (Fondaparinux),
and direct Factor Xa inhibitors (Rivaroxaban and Apixaban).
Factor VIII Inhibitor Bypassing Activity (FEIBA) should be
the first-line reversal agent in patients taking dabigtran [37].
PCC should be first-line in patients taking rivaroxaban and
rfVIIa for those on fondaparinux [37]. The effect of these anti-
platelet and reversal agents on incidence of CSDH and out-
comes from surgery is not yet known.
There is no quality evidence to guide the optimal timing of
post-operative resumption of antiplatelet therapy in patients
treated surgically for CSDH. Further prospective studies are
needed to provide evidence-based recommendations.
Choice of Anaesthesia
A small number of studies have examined the influence of
local (LA) and general anaesthesia (GA) on surgical CSDH
evacuation. A retrospective study of patients over 60 years old
undergoing BHC for CSDH demonstrated that cardiac com-
plications were significantly higher in the GA group, who
consequently had significantly longer hospital stays [40].
However, in another single-centre retrospective series of
1000 surgically treated patients, there was no significant dif-
ference in outcome between ‘monitored anaesthesia’ (LAwith
conscious sedation) and GA, although only 10% of patients in
this study actually underwent GA [10].
Comparisons of GA and regional/local anaesthesia have
been made in non-neurosurgical practice. For example, a re-
view of 18,715 geriatric patients undergoing hip fracture sur-
gery concluded that spinal anaesthesia is associated with sig-
nificantly reduced early mortality and a decreased risk of ve-
nous thromboembolism, delirium, myocardial infarction, pneu-
monia and post-operative hypoxia [41]. However, the GALA
trial (general anaesthesia versus local anaesthesia for carotid
surgery) failed to demonstrate a difference in outcomes (stroke,
myocardial infarction or death at 30 days) between GA and LA
in patients undergoing carotid surgery [42]. Interestingly, data
from patients in the UK national audit of CSDH suggests that
many have similar baseline characteristics to those included in
the GALA trial. For now, the anaesthetist and surgeon, in con-
sultation with the patient, must decide which anaesthetic tech-
nique to use on an individual basis. In the future, if it can be
demonstrated that a single TDC or BHC with subdural drain is
as effective as more extensive procedures, then the tolerability
and acceptability of LA may increase.
Time to Surgery
‘Elective & Emergency Surgery in the Elderly: An Age Old
Problem’, published in 2010 by the National Confidential
Enquiry into Patient Outcome andDeath (NCEPOD) highlight-
ed the increased risk of peri-operative morbidity and mortality
in the elderly (http://www.ncepod.org.uk/2010eese.htm). The
report demonstrated that delays in surgery are associated with
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poorer outcome and recommends that senior clinicians in
surgery, anaesthesia and medicine need to be involved in the
decision to operate on elderly patients. Integrated patient care
pathways can consolidate the involvement of these specialities
to optimise care. For example, these pathways are now the
standard of care for NHS patients presenting with a fractured
neck of femur and have been shown to reduce morbidity and
mortality as well as hospital length of stay [43]. The British
Orthopaedic Association and the British Geriatrics Society
also provide best practice guidelines in their ‘Blue Book’
publication [44]. Together with a Web-based National Hip
Fracture Database (NHFD), this permits trauma units to bench-
mark and improve their management of this patient population.
No such guidelines or resources exist for elderly patients
with CSDH and there is currently no evidence to guide best
practice on timing of surgery. Instinctively, the shorter the
duration of a neurological deficit, the quicker will a patient’s
recovery be and the more likely the deficit is to fully recover.
The relativemerits of early surgery need to beweighed against
the benefits of optimising the patient’s medical state for an-
aesthesia. Amulti-disciplinary integrated patient care pathway
to facilitate this is currently under development by The
National Hospital, London.
Post-operative Mobilisation
Early post-operative mobilisation of patients remains a con-
troversial issue. It is thought to reduce incidence of complica-
tions such as pneumonia and deep vein thromboses.
Conversely, bed rest has been proposed to reduce recurrence
by promoting brain re-expansion. A recent audit of UK prac-
tice found that 61 % of practitioners continue to prescribe bed
rest for a median of 12–24 h post-operatively, but the same
study also demonstrated that bed rest did not significantly
affect the rate of CSDH recurrence. In fact, bed rest predicted
poor outcomes (mRS 4–6) [17••]. Two prospective
randomised studies have also concluded that recurrence rates
after BHC are independent of patient’s post-operative posi-
tion, but another demonstrated a statistically higher recurrence
rate in patients mobilised immediately after surgery [5–7].
Reported complication rates as a result of early mobilisation
also vary between these studies. Intuitively, if early
mobilisation does not impact CSDH recurrence, then it should
be beneficial to patient recovery.
Conclusion: Time for a New Paradigm in CSDH
Management—an Evidence-Based Integrated Care
Pathway
We have demonstrated that many uncertainties remain as how
to best optimise operative and peri-operative care for elderly
patients with CSDH. Parallels to patients with fragility
fractures would suggest that we need an integrated, multi-
disciplinary approach, minimising delay to surgery, simplify-
ing the surgical approach and promoting early rehabilitation.
A better coordination of multi-disciplinary care should also
improve patient satisfaction in their treatment. Further work
to establish the standards to be included in an integrated care
pathway will need to address several important questions,
amongst them: Is there a benefit from early transfer to a neu-
rosurgical unit or from early surgery? Does routine access to
acute medical support on admission improve peri-operative
care? Is single burr hole drainage and insertion of a subdural
drain performed under monitored anaesthesia (local anaesthet-
ic with sedation) non-inferior/superior to multiple burr holes
performed under general anaesthetic? Is there an adjunctive
role for corticosteroids? Does early post-operative
mobilisation improve long term outcomes or increase CSDH
recurrence? Addressing these questions requires a coordinated
approach and we invite collaboration in our future work as we
endeavour to establish best practice for this vulnerable patient
population.
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